I hated ‘neuro’ as an undergraduate. My first exposure was the Nernst Equation and when coupled with the complexity of the brains connections my blood simply ran cold. Chapters on the central nervous system (CNS) in my textbooks went virtually unvisited (the picture above is of my original ‘pristine’ copy of Excitable Cells). Sadly, during the subsequent decades, neurological drug development failed to inspire me despite working on a broad variety of project. To me it seemed like the field has been defined by failure. However, as our understanding of the brain as a complex, dynamic system matures, computational approaches are beginning to reframe how we think about therapeutic discovery. But caution is warranted; the path forward demands integration, not hype.
A Tale of Two Therapeutic Landscapes
Over the past two decades, drug discovery has been transformed across multiple therapeutic areas. In oncology, the advent of targeted therapies, immune checkpoint inhibitors, and CAR-T cell therapies have dramatically altered survival trajectories for previously intractable malignancies [1][2]. Monoclonal antibodies have revolutionised the management of inflammatory and autoimmune diseases, from rheumatoid arthritis to psoriasis [3]. Cardiovascular medicine has similarly benefited from PCSK9 inhibitors and novel anticoagulants, while gene therapies and RNA-based therapeutics now offer curative potential for previously untreatable genetic disorders [4][5].
Yet this remarkable progress has largely bypassed the brain. Neurological and psychiatric disorders, encompassing Alzheimer's disease, Parkinson's disease, depression, schizophrenia, bipolar disorder, autism spectrum disorders, and motor neurone disease—remain stubbornly resistant to disease-modifying therapies [6]. The statistics are sobering: between 1995 and 2014, the approval success rate for central nervous system (CNS) drugs was only 6.2% versus an average 19.1% across all therapeutic areas [7].
The Burden We Cannot Ignore
The societal toll of neurological disorders is staggering and growing. Dementia alone affects approximately 55 million people globally, a figure projected to triple by 2050 as populations age [8]. Depression is the leading cause of disability worldwide, affecting an estimated 280 million individuals and contributing substantially to the global burden of disease [9]. Parkinson's disease prevalence has doubled over the past 25 years, with disability-adjusted life years increasing by 81% since 2000 [10].
Beyond healthcare costs, the human dimension is profound. Caregiver burden for dementia patients exceeds that of virtually any other chronic condition [11]. The cumulative economic impact of neurological disorders in Europe was estimated at €798 billion in 2010, with indirect costs, lost productivity, informal care, outstripping direct healthcare expenditure [12]. This is a crisis medicine has so far failed to address.
Why the Brain Is Fundamentally Different
The difficulty of CNS drug development is not merely a matter of complexity, it reflects a qualitative difference from other organ systems. As was clear to my undergraduate self, the brain is the most intricate biological structure known. It contains approximately 86 billion neurons and an equivalent number of glial cells, each forming thousands of synaptic connections [13]. This extraordinary cellular diversity, comprising hundreds of distinct neuronal subtypes, each with unique molecular signatures, connectivity patterns, and electrophysiological properties, fundamentally challenges reductionist approaches to drug discovery [14].
Unlike the liver, heart, or kidney, whose primary functions can be understood through relatively well-defined molecular pathways and can be readily modelled in vitro, the brain operates as a dynamic, distributed network where function emerges from the coordinated activity of multiple regions [15]. Neural circuits exhibit plasticity, redundancy, and homeostatic regulation that can compensate for perturbations, making the relationship between molecular targets and clinical outcomes profoundly indirect [16].
Functional experimentation has historically been far more challenging in the brain than in peripheral organs. The blood-brain barrier, while essential for homeostasis, severely restricts drug access; approximately 98% of small molecules and virtually all large biologics cannot cross it [17]. The inability to biopsy living brain tissue routinely, except in rare surgical contexts, has forced reliance upon indirect biomarkers and neuroimaging measures that capture only downstream consequences of pathology. Limited tissue accessibility has also constrained our understanding of human neurobiology, forcing reliance upon animal models whose predictive validity for drug response remains poor [18].
Perhaps most critically, the translation gap between preclinical models and human disease has proven exceptionally difficult to bridge. Transgenic mouse models of Alzheimer's disease, for example, have consistently failed to predict human clinical outcomes, with over 400 experimental therapies demonstrating efficacy in animals that ultimately failed in human trials [19]. This reflects not only species differences in neurobiology but fundamental divergences in how pathology manifests across the lifespan, in the context of the broader physiological and cognitive environment.
A Conceptual Reframing
Neuroscience is increasingly moving away from viewing the brain as simply another organ amenable to linear biochemical intervention. A conceptual shift is underway, driven by the recognition that the brain constitutes a complex adaptive system, a nested hierarchy of interacting components whose behaviour cannot be understood by studying parts in isolation [20].
This perspective has given rise to systems neuroscience, network biology, and the emerging discipline of computational neuroscience. For the worldly wise, tThe brain is now conceptualised as a series of dynamic functional networks, large-scale systems that reconfigure across timescales and in response to task demands, disease, and development [21]. Brain connectomics, enabled by advances in neuroimaging and graph theory, has revealed that neurological and psychiatric disorders are often characterised not by focal pathology but by distributed network disruptions [22]. Alzheimer's disease, for example, is increasingly understood as a disconnection syndrome, with network breakdown preceding and potentially contributing to clinical symptoms [23].
This network perspective is allowing us to reshape approaches to therapeutic discovery. Instead of seeking single molecular interventions, computational neuroscience offers the possibility of identifying targets whose modulation might restore network-level function. Speaking as a traditional clinical pharmacologist, this represents a fundamentally different therapeutic strategy with potentially broader clinical impact.
Progress Amid Uncertainty
Despite the challenges, considerable progress has been made in our molecular understanding of neurological diseases. Genome-wide association studies have identified hundreds of risk loci across psychiatric and neurodegenerative conditions, illuminating previously unanticipated pathways [24]. Transcriptomic and proteomic analyses have revealed molecular signatures associated with disease, while neuroimaging has provided in vivo windows onto structural and functional changes [25]. The identification of pathological protein aggregation, amyloid-beta and tau in Alzheimer's, alpha-synuclein in Parkinson's, TDP-43 in motor neurone disease, has defined common themes across neurodegeneration [26]. Neuroinflammation, complement pathway dysregulation, and synaptic dysfunction have emerged as convergent mechanisms [27]. Genetic discoveries such as APOE, TREM2, and LRRK2 have provided valuable entry points for therapeutic intervention.
Yet these advances have not translated into effective treatments. We still have only a partial understanding of causal disease mechanisms, the temporal ordering of pathological events, and the biochemical interactions that drive progression. Systems biology approaches have revealed unexpected interactions between pathways, suggesting that single-target interventions may be insufficient and that the complexity of the pathophysiology itself limits therapeutic success [28]. This uncertainty has contributed to exceptionally high failure rates in CNS drug development and demands a new approach to target identification and validation.
The Convergence Toward Computational Frameworks
Increasing understanding across multiple domains, genetics, molecular biology, neuroimaging, electrophysiology, cognition, behaviour, and real-world patient data, is converging into an integrated framework for drug discovery [29]. These complementary data streams are increasingly being analysed together, rather than independently, through computational neuroscience.
This convergence is enabling the development of multi-scale models that bridge molecular events, cellular dynamics, circuit-level activity, and clinical phenomena. Digital twins of the brain, personalised computational models incorporating genetic, imaging, and behavioural data, are beginning to emerge as tools for predicting disease trajectories and treatment responses [30]. Foundation models trained on large-scale biomedical data are increasingly capable of integrating diverse data types, identifying patterns invisible to conventional analyses, and generating hypotheses about disease mechanisms and therapeutic targets.
Machine learning is already improving patient stratification in clinical trials, identifying predictive biomarkers, and enabling adaptive trial designs that are constantly adjusting to accumulating evidence [31]. Wearable devices and smartphone-derived behavioural biomarkers offer the prospect of continuous monitoring, capturing fluctuations in function that are invisible to conventional clinical assessments.
Importantly, these computational approaches are being combined with advances in therapeutic modalities. RNA therapeutics, gene editing, and cell therapies offer the potential to target fundamental disease mechanisms, while targeted delivery technologies may overcome the blood-brain barrier [32]. The integration of these molecular innovations with computational frameworks may finally enable the precise, patient-specific interventions that have eluded neuroscience.
A Realistic Path Forward
Neuroscience remains one of the most difficult scientific frontiers and yet, I believe we stand on the threshold of real progress. The complexity of the brain, the limitations of current models, and the challenging translational landscape mean that progress will be incremental rather than revolutionary. Future breakthroughs are unlikely to arise from single discoveries, whether molecular, genetic, or computational, but from integrating biology with computational modelling, artificial intelligence with longitudinal patient data, and wearable technologies with precision medicine approaches [33].
Computational neuroscience is becoming not merely another research discipline but the organising framework through which neurological drug discovery may finally become more predictive and successful. This transition requires sustained investment in data generation and integration, continued development of computational methods, and, crucially, maintenance of scientific rigour amid growing enthusiasm for AI. The brain's complexity demands humility, but it also offers an unprecedented opportunity: a future in which we understand the brain sufficiently to intervene meaningfully, rather than simply treating its symptomatic failings.
The path forward is challenging, and the failures of the past caution against overconfidence. But for the first time, we have both the tools and the conceptual framework to tackle neuroscience's greatest therapeutic challenges. The future of drug discovery may indeed depend on understanding the brain, not in the simplistic sense of identifying molecular targets, but in the comprehensive, multi-scale, systems-level appreciation that computational neuroscience can provide.
References
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
